Roh Hyun-Jin, Suh Dong-Soo, Choi Kyung-Un, Yoo Hang-Jo, Joo Won-Deok, Yoon Man-Soo
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Republic of Korea.
J Obstet Gynaecol Res. 2011 Jul;37(7):851-60. doi: 10.1111/j.1447-0756.2010.01452.x. Epub 2011 Mar 31.
The aim of this study was to evaluate O⁶-methyguanine-DNA methyltransferase (MGMT) promoter hypermethylation, MGMT expression and microsatellite instability (MSI), as well as to elucidate their correlation with clinical and pathological parameters in epithelial ovarian cancer.
Ovarian cancer tissue specimens (n = 86) were obtained after a staging operation. The MGMT gene was investigated by methylation-specific polymerase chain reaction (MSP) and MGMT expression status was analyzed using immunohistochemistry. MSI status was examined by the fluorescence-based PCR using five National Cancer Institute markers.
Negative MGMT expression was detected in 12 of 86 (14.0%) epithelial ovarian cancers. In 34 cases where MSP results were available, MGMT promoter hypermethylation was detected in five cases (14.7%) with mucinous or clear cell carcinomas, but not in any of other histological types (P = 0.031). Five out of six cases with negative MGMT expression showed MGMT promoter hypermethylation, whereas all of the 28 cases that retained expression of MGMT were unmethylated at the MGMT CpG island (P < 0.001). In 41 cases of MSI results available, seven (17.1%) cases showed MSI-H-phenotyped. Both MGMT promoter hypermethylation and negative MGMT expression were noted only in cases of mucinous or clear cell carcinoma in which MSI status were mostly MSS-phenotyped; however, no significant correlation was found between MSI status and clinicopathological parameters.
Negative MGMT expression was significantly correlated with MGMT promoter hypermethylation in MSS-phenotyped tumors of mucinous or clear cell carcinoma. The results suggest that MGMT promoter hypermethylation might be associated with epithelial ovarian carcinogenesis in specific histological types.
本研究旨在评估O⁶-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子高甲基化、MGMT表达及微卫星不稳定性(MSI),并阐明它们与上皮性卵巢癌临床和病理参数的相关性。
86例卵巢癌组织标本于分期手术后获取。采用甲基化特异性聚合酶链反应(MSP)检测MGMT基因,并运用免疫组织化学分析MGMT表达状态。通过基于荧光的PCR使用五种美国国立癌症研究所标志物检测MSI状态。
86例上皮性卵巢癌中有12例(14.0%)检测到MGMT表达阴性。在可获得MSP结果的34例中,5例(14.7%)黏液性或透明细胞癌检测到MGMT启动子高甲基化,而其他组织学类型均未检测到(P = 0.031)。MGMT表达阴性的6例中有5例显示MGMT启动子高甲基化,而保留MGMT表达的28例中所有病例在MGMT CpG岛均未甲基化(P < 0.001)。在可获得MSI结果的41例中,7例(17.1%)显示为MSI-H表型。MGMT启动子高甲基化和MGMT表达阴性仅在黏液性或透明细胞癌中被观察到,其中MSI状态大多为MSS表型;然而,未发现MSI状态与临床病理参数之间存在显著相关性。
在黏液性或透明细胞癌的MSS表型肿瘤中,MGMT表达阴性与MGMT启动子高甲基化显著相关。结果表明MGMT启动子高甲基化可能与特定组织学类型的上皮性卵巢癌发生有关。